For the effective use of 1311 in the treatment of thyroid cancer, adequate organification of the radioisotope by tumour tissue is essential. Most thyroid tumours even though differentiated, are usually nonfunctional initially when normal thyroid tissue is still present. Subsequently a tumour often develops the ability to concentrate 1311 although usually only if stimulated by supranormal levels of TSH (Edmonds et al., 1977) . Unfortunately there is no satisfactory way of predicting at an early stage whether a particular tumour will eventually develop sufficient capacity for 1311 concentration. Thyroglobulin production and the presence of TSH receptors on the plasma membranes are two properties indicative of potentially functioning tissue and we have compared these characteristics with the radioiodine uptakes observed during treatment.
Materials and methods
All patients attended the Thyroid Clinic in the Department of Radiotherapy and Oncology at University College Hospital and were subsequently on long term follow up. The treatment protocol was initial thyroidectomy with removal of as much tumour as possible followed by therapy and test doses of 1311 as previously described (Edmonds et Corbett et al. (1956) but having a sodium iodide scintillator with a rectangular slit collimator perpendicular to the long axis of the patient was used to estimate the amount of 1311 concentrated at any site. Scanning by gamma camera was also carried out over appropriate regions. Measurements were done at 2 and at 5 to 7 days after the 1311 administration; the delayed measurements allowed excretion of 1311_ iodide so that low levels of functional activity could be determined. The lower limit of sensitivity of localized concentrations detectable was 0.2-0.8 MBq (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .
Fresh human thyroid tissue, tumour and/or lymph nodes were obtained at operation and subsequently classified into their pathological type on the basis of histological examination (kindly performed in the Department of Pathology, University College, London, School of Medicine). Specimens were, in addition, placed on ice and membrane extracts prepared which were later used for measurement of TSH binding capacity and for assessment of binding characteristics: the methods were as those previously described in detail (Kermode & Thompson, 1980; Kermode et al., 1981) . Normal (Smith & Hall, 1974) .
Results

TSH binding
The tumours of all the six patients with differentiated cancer had demonstrable specific binding of 1251-labelled bTSH and, on most, the binding percentage differed little from the normal value (Table I ). The lowest binding was in a tumour of patient 5 but this tumour was also less well differentiated than the others. Of the six patients studied, one (la, b, Table I and Figure 1) provided two specimens, the first obtained at the initial thyroidectomy, the second two and a half years later when recurrent lymph nodes were removed. The two specimens had similar histological appearance and bTSH binding.
The binding of human TSH (hTSH) was also examined in all of the samples. The general pattern of variation was similar but the binding percentage was considerably less. Thus for the normal tissues average binding was 33.6 + 9.9% using bTSH compared with 7.9 + 3.2% using hTSH; for the differentiated tumours, binding averaged 30 + 7.1% for bTSH compared with 8.2 + 2.1% for hTSH. Similar differences in binding have been previously , 1984) .
The binding affinity and capacit by measurement of the suppressior 1251-labelled bTSH in the presence o0 centration of non-radioactive bTSI data were consistent with the 'or model for TSH-receptor interaction Scatchard plot (Scatchard, 1949 (Fui et al., 1979) . On this basis, the patients 1, 4 and 6 had evidence of tumour Tg production. In patient 1 her high level of serum Tg was associated with a tumour which concentrated 131I relatively well although, as indicated by % of 131I dose concentrated g-1 tissue, the concentration was low compared with that of normal thyroid tissue despite enhanced TSH stimulation. In this patient, both aspects of thyroid cell function were evidently present. By contrast in the other two patients, 4 and 6, no 131I concentrating function was detectable in the tumours although the TSH receptors were well within the normal range in the tumours of these patients. Studies of the iodine content of Tg derived from tumour tissue have shown that it may be very low (Schneider et al., 1983) an observation which, together with the present results, indicates that the retention of Tg secreting activity by the tumour does not necessarily mean that the tumour will concentrate iodine well.
In conclusion, our observations show that the presence of a normal complement of TSH receptors does not indicate that iodine concentration will occur even when plasma TSH levels are much elevated. The mediating factors between the TSHreceptor complex and iodide trapping and organification are presumably inadequate in some tumour cells. Secretion of Tg by tumour tissue, in contrast to normal thyroid tissue, appears to be largely independent of TSH control. Moreover considerable Tg secretion may occur from some tumours which have little or no functional iodine concentrating mechanism even though stimulated by high plasma TSH concentrations. Nevertheless, in the majority of patients, the capacity of the tumour to secrete Tg does appear to indicate that it will also concentrate iodine although the relationship between these two cellular functions varies considerably from one tumour to another.
